Premier Endpoint works with best-in-class affiliates with proven success
to provide customized solutions for our clients.
High Touch Investor Relations (HTIR) is a boutique Investor Relations firm based in New York City. What sets High Touch IR apart is our credo “Quality not Quantity”. HTIR limits their number of clients to ensure each gets full-service attention to complete their goals. Whether its seeking IR Services to increase liquidity and fair valuation for your stock, raise capital or seek out Marketing and IR Strategy to increase your visibility, HTIR will work with management to achieve their capital markets goals.
HTIR 5-Step Transformative IR Plan™
HTIR has developed a proprietary transformative investor relations plan that is exclusive to companies that contract with them. In order to benefit fully from the plan, HTIR recommends an 18 to 24-month initial retainer. Why? Their more than 20 years of working in customized investor relations plans has proven that to truly transform a company’s reputation and valuation, it takes laser focus and commitment. That means customized analysis, strategy formation, materials development, implementation, and results measurement to truly optimize your company’s value.
Laura Kiernan, IRC, CPA, the CEO and Founder of High Touch IR, has more than two decades of experience as an Investor Relations expert. She was named #2 Best Overall IRO for Mid-Cap Technology Media & Telecom (TMT) All American Management Team 2019 by Institutional Investor. High Touch IR is one of OTC Markets Group’s Preferred Providers for Investor Relations. Please visit their website, HighTouchIR.com, for more information.
Now Biopharma, LLC, is a Clinical CRO and Life Science Consultancy headquartered in New Jersey, USA. The clinical CRO specializes in performing phase-2 , -3, and -4, acute care clinical trials (e.g., cardiovascular, neurology, infectious disease), while the consultancy provides services in life-science entrepreneurship, C-level management, strategy, scientific affairs, regulatory affairs, clinical development, facilitation, and quality operations.
Richard Prince, Ph.D., is the CEO of Now Biopharma. His previous management/executive roles in industry are multivariate, spanning start-up to commercial companies, small molecule and large molecule programs, as well as the service and product sectors of the healthcare industry. Dr. Prince previously worked at Gibraltar Laboratories (a contract testing laboratory, now part of Nelson Laboratories), Microgen, Inc. (a specialty chemical firm), Mayne Pharma (a generic drug firm, now part of Pfizer), and Prolong Pharmaceuticals (a hematology and oncology biotech startup). He has also consulted extensively for multiple ‘Big Pharma’ companies operating under Warning Letters and Consent Decrees issued by the FDA. Dr. Prince received his B.A. (Microbiology) and Ph.D. (Zoology & Physiology with specialization in Tumor Immunology) from Rutgers University.
Dr. Prince is a well-known author and editor within the Parenteral Drug Association (PDA) community, with five published textbooks in the areas of microbiology (two editions), quality, variability, and biotechnology. His microbiology text remains the top-selling text in the history of the PDA.